Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma (NHL) subtype with aggressive clinical demonstration characterized by the expression of neoplastic B-cell markers such as CD5, CD19, CD20, CD79, and BSAP/PAX5^[@CR1],[@CR2]^. Notably, CD20 is strongly expressed by neoplastic B cells, enabling this cell surface protein to be exploited as a therapeutic target^[@CR3]^. Targeting CD20 with anti-CD20 monoclonal antibodies such as rituximab has shown clinically meaningful outcomes^[@CR4]--[@CR7]^. To enhance antibody-mediated therapy, immunotoxins are utilized as an innovative cancer therapy tool that links an antibody or antibody fragment with a toxin, selectively localizing the toxin to the target cells to induce lethality^[@CR8]^.

MT-3724, an engineered toxin body (ETB) comprised of a modified cytotoxic Shiga-like toxin 1A (3F7) and a CD20-specific single-chain variable fragment (scFv), recognizes CD20-expressing cells and triggers protein synthesis inhibition and apoptosis^[@CR9]--[@CR12]^. Although targeted therapy such as Bruton's tyrosine kinase (BTK) inhibition by ibrutinib has achieved high response rates (68%) in relapsed/refractory MCL, therapeutic resistance has emerged as a barrier to improved patient outcomes and survival^[@CR13]^. MT-3724 has the potential to bypass possible resistance mechanisms mediated via acquired BTK mutations or the activation of alternative survival signaling pathways by inhibiting tumor growth and survival through toxin-mediated activity^[@CR14],[@CR15]^. To assess the anti-MCL effects of MT-3724, we tested its in vitro and in vivo efficacy in MCL cell lines and patient-derived xenograft (PDX) mouse models.

To correlate MT-3724 cytotoxicity with CD20 expression, CD20 surface expression was examined across 8 MCL cell lines (Supplementary Fig. [S1A](#MOESM3){ref-type="media"}), and the CD20 MFI varied among different cell lines (Supplementary Fig. [S1B](#MOESM3){ref-type="media"} and Supplementary Table [S1](#MOESM2){ref-type="media"}). Four cell lines were treated with two MT-3724 doses for 24 h, resulting in undetectable CD20 expression, suggesting complete occupation of CD20 with MT-3724 (Supplementary Fig. [S1C](#MOESM3){ref-type="media"}). We next verified whether MT-3724 induces cytotoxic activity against MCL. Indeed, MT-3724 inhibited the growth of MCL cell lines dose dependently (Fig. [1a](#Fig1){ref-type="fig"}), with the MT-3724 IC~50~ value ranging from 78 to 1383 ng/mL (Supplementary Table [S1](#MOESM2){ref-type="media"}). No negative correlation between the IC~50~ and CD20 MFI was observed among the MCL cell lines (Supplementary Fig. [S1D](#MOESM3){ref-type="media"}). However, no significant difference in the MT-3724 IC~50~ values was observed among the ibrutinib-sensitive and ibrutinib-resistant cell lines (Fig. [1b](#Fig1){ref-type="fig"}). Furthermore, 300 ng/mL MT-3724 was sufficient to reduce cell growth over time (Fig. [1c](#Fig1){ref-type="fig"}).Fig. 1MT-3724 inhibits the growth of MCL cells in vitro and in vivo.**a** Cell viability of 8 MCL cell lines following 72 h treatment with the indicated increasing concentrations of MT-3724 (ibrutinib-sensitive cell lines: green; -resistant cell lines: red). **b** Comparison of the MT-3724 IC~50~ values among ibrutinib-sensitive (green) and --resistant (red) cell lines. **c** Time-dependent cell viability analysis (24 h, 48 h and 72 h assays) of 4 MCL cell lines treated with the indicated concentrations of MT-3724 (ibrutinib-sensitive cell lines: green; ibrutinib-resistant cell lines: red). **d, e** Apoptosis induction in Jeko-1 and Jeko-R cells treated with the indicated doses of MT-3724 for 24 h as measured by Annexin V/PI staining and flow cytometry. **f, g** Cell cycle arrest measured by PI staining in cell lines treated with 500 ng/mL MT-3724. Each treatment for cell viability, apoptosis and cell cycle was set up triplicate and conducted at least 3 independent times. **h** Immunophenotyping of MCL PDX tissue was conducted by two-color flow cytometry. Cells derived from the PDX were labeled CD5, CD20 single antibody or antibody combination. **i** Efficacy of single agent MT-3724 in a MCL PDX mouse model. PDX mice were treated IP with 1.2 mg/kg/dose MT-3724 or vehicle control for 5 days/week every other week for 4 weeks. Tumor volume was measured every week. *N* = 5 per treatment group. **j** Kaplan-Meier survival curves of the individual groups of mice. P values less than 0.05 indicate statistical significance. IBN: ibrutinib

Shiga toxin triggers mitochondrial stress *via* various cellular mechanisms such as decreasing anti-apoptotic protein levels, including MCL-1 and BCL-2^[@CR16]--[@CR18]^. To investigate whether MT-3724 induces apoptosis or cell cycle arrest in MCL, one pair of cell lines (Jeko-1 and Jeko-R) was treated with different MT-3724 doses for 24 h. As previously reported, Jeko-R is an acquired ibrutinib-resistant MCL cell line generated through chronic exposure to low ibrutinib concentrations^[@CR19]^. MT-3724 induced apoptosis, and the percentage of apoptotic cells (Fig. [1d--e](#Fig1){ref-type="fig"}) and caspase 3/7 expression (Supplementary Fig. [S2A-B](#MOESM4){ref-type="media"}) correlated with dosage in both cell lines. MT-3724-induced PARP cleavage and reduced BCL-2 and MCL-1 expression dose dependently (Supplementary Fig. [S2C](#MOESM4){ref-type="media"}). MT-3724 has been suggested to inhibit protein synthesis and block the cell cycle^[@CR20]^; therefore, we assessed the cell cycle effects of MT-3724 and found that both Jeko-1 and Jeko-R cells arrested in G0/G1 (Fig. [1f, g](#Fig1){ref-type="fig"}). To evaluate the in vivo efficacy of single agent MT-3724, an ibrutinib-resistant PDX model expressing high levels of CD5 and CD20 antigens (Fig. [1h](#Fig1){ref-type="fig"}) was treated with MT-3724, resulting in significantly reduced tumor volume and increased overall survival compared with the control (Fig. [1i, j](#Fig1){ref-type="fig"}). These in vivo results indicate that MT-3724 has the potential to overcome therapeutic resistance, demonstrating the strong potential for the clinical application of this ETB in MCL treatment.

To investigate the the anti-MCL effects of MT-3724, Jeko-1, Jeko-R and Z-138 cells treated with 1000 ng/mL MT-3724 for 24 h were subjected to reverse phase protein array (RPPA), and Ingenuity Pathway Analysis (QIAGEN Bioinformatics) was performed. Overall, 63 pathways comprising 307 proteins were analyzed (Supplementary Fig. [S3A](#MOESM5){ref-type="media"} and Supplementary Table [S2](#MOESM2){ref-type="media"}). Jeko-1 shared three downregulated pathways with Jeko-R (PI3K/AKT signaling, mitotic roles of Polo-Like Kinase and angiopoietin signaling) and one downregulated pathway (mitotic roles of Polo-Like Kinase) with Z-138, and the three cell lines shared one downregulated pathway (mitotic roles of Polo-Like Kinase) between the negative controls and the MT-3724-treated cells lines (upper panel Supplementary Fig. [S3B](#MOESM5){ref-type="media"}). Jeko-1 shared six upregulated pathways with Jeko-R and Z-138, but only one upregulated pathway (sumoylation pathway) was shared among the three cell lines (bottom panel Supplementary Fig. [S3B](#MOESM5){ref-type="media"}). Jeko-1 shared more dysregulated pathways with Jeko-R than with the less sensitive cell line Z-138. We further analyzed several dysregulated pathways such as the PI3K/AKT, PTEN and apoptotic pathways, in which the components of the PI3K/AKT and apoptotic pathways were significantly different in Jeko-1 and Jeko-R cells but not in Z-138 cells (Supplementary Fig. [S3C](#MOESM5){ref-type="media"}). Furthermore, several proteins (MCL-1 and cleaved caspases 3 and 7) deregulated in the RPPA analysis post-MT3724 treatment were also dysregulated in the apoptosis assays (Supplementary Fig. [S2](#MOESM4){ref-type="media"}).

Ibrutinib resistance is a major therapeutic issue in MCL^[@CR21],[@CR22]^; therefore, therapies to prevent and overcome resistance can have important clinical applications. We assessed the synergistic activity of ibrutinib and MT-3724 in two ibrutinib-resistant cell lines. The combination achieved strong synergy in cell viability assays, with the Ki values \< 1 (Fig. [2a, b](#Fig2){ref-type="fig"} and Supplementary Fig. [S4E](#MOESM6){ref-type="media"}), and in the induction of apoptosis (Fig. [2c, d](#Fig2){ref-type="fig"} and Supplementary Fig. [S5A-B](#MOESM7){ref-type="media"}). We also confirmed the synergistic activity between ibrutinib and MT-3724 in additional ibrutinib-resistant cell lines (Supplementary Fig. [S4A-B](#MOESM6){ref-type="media"}). Moreover, MT-3724 reduces the expression of the anti-apoptotic BCL-2 and MCL-1 (Supplementary Fig. [S2C](#MOESM4){ref-type="media"}); therefore, MT-3724 and ABT-199 may synergistically induce apoptosis, serving to overcome ibrutinib resistance. We determined the synergistic activity of the combination in two ibrutinib-resistant cell lines, Granta519 (ABT-199-sensitive) and Jeko-R (ABT-199-resistant). Synergistic effects on growth inhibition (Fig. [2e, f](#Fig2){ref-type="fig"}) and apoptosis were observed (Fig. [2g, h](#Fig2){ref-type="fig"} and Supplementary Fig. [S5C-D](#MOESM7){ref-type="media"}). MT-3724 and ABT-199 also had synergistic effects on two additional ibrutinib-resistant MCL cell lines, Z-138 and Maver-1 (Supplementary Fig. [S4C-D](#MOESM6){ref-type="media"}). These data suggest that MT-3724 sensitizes MCL cells to ibrutinib treatment and synergistically induces cytotoxicity with ibrutinib or ABT-199.Fig. 2**MT-3724 in combination with ibrutinib or ABT-199 synergistically induces growth inhibition and apoptosis in therapeutic-resistant MCL cells**.**a, b** Cell viability of Jeko-R and Z-138 cells treated with single agents (MT-3724 and ibrutinib) or the combination. **c, d** Apoptosis induction of Z-138 and Jeko-R cells treated for 24 h with single agents (MT-3724 and ibrutinib) or the combination. IBN: 5 μM; MT-3724: 500 ng/mL. **e, f** Dose-dependent cell viability analysis of Granta519 and Jeko-R cells treated with single agents (MT-3724 and ABT-199) or the combination. **g, h** Apoptosis detection of Granta519 and Jeko-R cells treated for 24 h with single agents (MT-3724 and ABT-199) or the drug combination. ABT-199: 10 nM; MT-3724: 500 ng/mL. Each cell viability and apoptosis experiment was set up in triplicate and conducted two independent times

MT-3724, an engineered CD20 toxin antibody, combines targeted therapy with immunotherapy to increase efficacy. In our study, MT-3724 inhibited MCL cell growth in vitro and in vivo. All tested MCL cell lines expressed high CD20, with 6 out of 8 cell lines displaying sensitivity to MT-3724. The potential mechanisms of resistance in cells highly expressing CD20 may include mutations in CD20, structural changes affecting the binding region or alterations in the cell membrane. Post-MT-3724 treatment, the PI3K/AKT and apoptosis pathways were dysregulated in Jeko-1 and Jeko-R cells but not in the MT-3724-insensitive Z-138 cells. Several pathways were found dysregulated only in Z-138 cells, such as ILK signaling, PAK signaling, BRCA1-mediated DNA damage response and regulation of actin-based motility by Rho, suggesting that these pathways may be associated with MT-3724 resistance. Ibrutinib and venetoclax are current treatment options for MCL^[@CR13],[@CR23]^; therefore, we combined MT-3724 with ibrutinib or venetoclax, which showed strong synergistic activity in both ibrutinib-resistant and venetoclax-resistant MCL cell lines. MT-3724 significantly reduced tumor burden and prolonged survival in a refractory MCL PDX mouse model, indicating that MT-3724 can reduce tumor burden in a model highly resistant to other therapies. MT-3724 has entered a Phase I/Ib study in NHL and has displayed promising single agent results^[@CR10]^. Our preclinical examination of MT-3724 alone and in combination with ibrutinib or venetoclax highlights its translational relevance for MCL treatment.
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